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Abstract
Background—Kenya has an estimated 13,000 new infant HIV infections that occur annually. 
We measured the burden of HIV infection among women of childbearing age and assessed access 
to and coverage of key prevention of mother-to-child transmission interventions.
Methods—The second Kenya AIDS Indicator Survey was a nationally representative 2-stage 
cluster sample of households. We analyzed data from women aged 15–54 years who had delivered 
a newborn within the preceding 5 years and from whom we obtained samples for HIV testing.
Results—Of 3310 women who had ≥1 live birth in the preceding 5 years, 2862 (86.5%) 
consented to HIV testing in the survey, and 171 (6.1%) were found to be infected. Ninety-five 
percent received pre-natal care, 93.1% were screened for HIV during prenatal care, and of those 
screened, 97.8% received their test results. Seventy-six women were known to be infected in their 
last pregnancy. Of these, 54 (72.3%) received antepartum antiretroviral prophylaxis, and 51 
(69.1%) received intrapartum prophylaxis; 56 (75.3%) reported their newborns received 
postpartum prophylaxis. Of the 76 children born to these mothers, 63 (82.5%) were tested for HIV 
at the first immunization visit or thereafter, and 8 (15.1%) were HIV infected.
Conclusions—We found a substantial burden of HIV in Kenyan women of childbearing age and 
a cumulative 5-year mother-to-child transmission rate of 15%. Although screening has improved 
over the past 5 years, fewer than three-quarters of infected pregnant women are receiving 
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antiretroviral prophylaxis. Universal antiretroviral therapy for HIV-infected pregnant women will 
be essential in achieving Kenyan’s target to eliminate mother-to-child transmission to <5% by 
2015.
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INTRODUCTION
In 2011, an estimated 330,000 children became newly infected with HIV worldwide.1 Over 
90% of these infections were acquired through mother-to-child transmission (MTCT), and 
more than 90% of these occurred in sub-Saharan Africa.1,2 Worldwide, HIV accounts for 
1.5% of all deaths in infants younger than 12 months of age and 4.9% of deaths in 1- to 4-
year-old children.3 Kenya is among the 22 countries that collectively account for 90% of all 
pregnant women living with HIV. The country accounts for 4% of all new pediatric HIV 
infections globally and 7% of all child deaths, and each year an estimated 13,000 new HIV 
infections occur among Kenyan children.4 Kenya has subscribed to the Global Plan 
Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their 
Mothers Alive, which seeks to reduce MTCT to below 5% by 2015 and prevent mothers 
from dying.5 For these goals to be realized, more than 90% of HIV-infected women need to 
be identified through screening and receive antiretroviral drugs and other interventions for 
prevention of MTCT (PMTCT).
MTCT can occur during pregnancy, labor and delivery or post-natally through 
breastfeeding. The risk of MTCT can be reduced to <5% using a comprehensive PMTCT 
strategy.6 In 2012, Kenya launched a plan for elimination of MTCT which involved the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) 4-pronged strategy that includes 
(1) providing HIV prevention services for women of reproductive age with reproductive 
health services; (2) opt-out HIV testing during pregnancy and, for HIV-infected pregnant 
women, access to antiretroviral prophylaxis during pregnancy and the immediate postpartum 
period, safe delivery methods, anti-retroviral prophylaxis for infants during breastfeeding, 
and promotion of exclusive, rather than mixed, breastfeeding; (3) provision of 
contraceptives to women living with HIV for family planning; and (4) provision of 
treatment, care, and support for women and children living with HIV infection and their 
families.5 Coverage of HIV testing among pregnant women in Kenya is now above 80%, but 
the incidence of MTCT at 18 months of age was estimated to be as high as 15% in 2011.7,8 
In the absence of complete longitudinal follow-up data for HIV-exposed children, HIV 
incidence in infants attributable to MTCT has only been inferred from early infant diagnosis 
at the first immunization visit or from cohort data at a few selected sites.9 As part of the 
strategy to reduce MTCT to <5% by 2015 and reduce HIV-related maternal mortality, 
Kenya is in the process of adopting the World Health Organization’s recommendation of 
providing lifelong antiretroviral therapy (ART) for HIV-infected pregnant and breastfeeding 
women.10
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In 2012, PMTCT programs were available in 4622 sites, representing 95% of all medical 
facilities that offered prenatal or obstetrical care in the country [Personal communication, 
National AIDS and Sexually Transmitted Infection Control Programme (NASCOP), Kenya 
Ministry of Health, June 27, 2013]. With the expansion of PMTCT, there is need for a more 
comprehensive examination of the impact of PMTCT on perinatal transmission. We 
evaluated data collected from the second Kenya AIDS Indicator Survey (KAIS 2012) to 




We conducted a national population-based cross-sectional household survey in 9 of 10 
NASCOP programmatic regions of Kenya from October 2012 to February 2013. Details of 
the survey design and execution are presented elsewhere.11 Briefly, we used a 2-stage 
cluster sampling design; in the first stage, we selected geographical clusters from Kenya 
National Bureau of Statistics’ household-based sampling frame using systematic random 
sampling, and in the second stage households were randomly selected from the chosen 
clusters. Eligible households were invited to participate in the survey. In this article, we 
present data obtained from interviews with female respondents who had delivered live-born 
children within the 5 years preceding the survey.
Study Population
We interviewed all women residing in an eligible household who were aged 15–54 years 
and who had 1 or more live births within the 5 years preceding the survey. We also obtained 
blood samples from consenting women for HIV testing at the National HIV Reference 
Laboratory (NHRL) in Nairobi.
Measures
We obtained verbal informed consent for survey procedures before the interview. Trained 
research assistants administered a structured questionnaire in English, Kiswahili, or other 
local languages where necessary. The questionnaire covered multiple domains, including 
sociodemographic characteristics, parity and place of delivery, antenatal care (ANC) clinic 
visits, and history of HIV testing. For those who self-reported that they were infected with 
HIV, we asked additional questions regarding use of ART for their own health, antiretroviral 
prophylaxis use by the mother and her infant, breastfeeding behavior, and family planning 
practices. These women were also asked whether their infants had been tested for HIV at 
their first immunization visit or thereafter and, if tested, the HIV test result. We recorded all 
information on portable laptop computers (Mirus Innovations, Mississauga, Ontario, 
Canada).
Laboratory Testing
Blood specimens were tested for HIV antibody at NHRL using Vironstika HIV-1/2 Enzyme 
Immunoassay (BioMerieux, Marcy l’Etoile, France) as the screening assay and Murex HIV.
1.2.0 Enzyme Immunoassay (DiaSorin, SpA, Saluggia, Italy) as the confirmatory assay. 
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Specimens that tested HIV-negative by the screening assay were classified as HIV-negative. 
Specimens that tested HIV-positive by the screening assay were tested by the confirmatory 
assay, and, if they tested positive on the confirmatory assay, they were classified as HIV-
positive. Specimens that were discordant on the screening and confirmatory assays were re-
tested using the same testing algorithm. If results remained discrepant, polymerase chain 
reaction (Cobas Amplicor HIV-1 Monitor Test, version 1.5; Roche Molecular Diagnostics, 
Pleasanton, CA) was used to determine the final result.
Data Analysis
We assessed both access to and coverage of PMTCT interventions at ANC clinics. We 
defined access as the proportion of women who self-reported that they had been diagnosed 
with HIV during or before the last pregnancy and who reported that they or their infants had 
received antiretro-viral prophylaxis or ART. We excluded from the analysis women who 
reported a previous diagnosis of HIV infection but were found to be HIV-negative by 
laboratory testing in the survey (N = 8). Women who reported a previous diagnosis of HIV 
infection but did not consent to a blood sample were included in the analysis (N = 8). We 
defined coverage as the proportion of women that tested positive for HIV in KAIS 2012, 
regardless of whether they knew that they were infected or not, who themselves or their 
infants had received any anti-retroviral prophylaxis or ART. We conducted a subanalysis of 
women who reported the birth of the child within the 2 years preceding the survey to better 
approximate the HIV status of the woman at the time of her last pregnancy.
We analyzed data from respondents using survey procedures in SAS version 9.3 (SAS 
Institute, Cary, NC). To minimize recall bias, we restricted our analysis to information about 
the most recent reported birth. We weighted estimates to account for the survey’s cluster 
design and calculated population proportions and 95% confidence intervals (CI). Statistical 
significance in cross tabulations was assessed based on Rao–Scott χ2 P values.
Ethical Considerations
Adult participants aged 18 years and older consented separately for the interview, blood 
draw, and HIV testing. Minors aged 15–17 years provided assent for these procedures with 
parental or guardian consent unless they were pregnant, married, or parents, in which case 
they were allowed to provide consent as adults for participation. HIV test results from the 
laboratory were merged with the survey database using a unique study identification 
number. The KAIS 2012 protocol was approved by the Ethics and Research Committee of 
the Kenya Medical Research Institute (KEM-RI), the Institutional Review board of the U.S. 
Centers for Disease Control and Prevention (CDC), and the Committee on Human Research 
of the University of California, San Francisco (UCSF).
RESULTS
We identified 8301 potentially eligible women between the ages of 15 and 54 years, and 
7429 (89.4%) were interviewed. Of these women, 3310 (44.5%) reported they had at least 1 
live birth in the 5 years preceding the survey and provided interview information about their 
last birth. The median age of women interviewed was 27 years (interquartile range, 23–33 
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years). The majority (83.2%, 95% CI: 81.6 to 84.7) of women were either married or 
cohabiting with a partner, and 90.7% (95% CI: 89.0 to 92.4) were in a monogamous 
relationship (Table 1). About half (47.1%, 95% CI: 44.4 to 49.8) had completed secondary 
education or higher, 29.1% (95% CI: 26.0 to 32.2) resided in the Rift Valley region, and 
65.1% (95% CI: 62.2 to 68.0) lived in rural settings.
Of the 3310 participants who had had at least 1 live birth in the previous 5 years, 2862 
(86.5%) consented to having a blood sample collected for HIV testing in a laboratory (Table 
2). The HIV prevalence for these women was 6.1% (95% CI: 4.9 to 7.4), which was lower 
than women aged 15–54 years who did not have a live birth (7.9%, 95% CI: 6.7 to 9.0) (χ2 = 
4.4, P = 0.03, df = 1). HIV prevalence increased significantly with older age group (χ2 = 9.0, 
P = 0.03, df = 3) and was significantly higher among widowed respondents at 23.6% (95% 
CI: 9.3 to 37.9) compared with other marital categories (χ2 = 31.5, P < 0.0001, df = 3). 
Women who had no formal education had significantly lower prevalence (1.3%, 95% CI: 
0.1 to 2.6) than women with higher education levels (χ2 = 9.8, P = 0.02, df = 3). Women 
living in Nyanza region had significantly higher prevalence at 18.5% (95% CI: 12.2 to 24.9) 
than women living in other regions (χ2 = 102.7, P < 0.0001, df = 8). HIV prevalence was 
similar by rural/urban residential settings (χ2 = 0.64, P = 0.42, df = 1), but significantly 
higher among women who did not want more children in the future (8.7%, 95% CI: 6.6 to 
10.8) compared with women who desired more children (4.0%, 95% CI: 2.7 to 5.2) or were 
unsure (2.0%, 95% CI: 0.2 to 3.8) (χ2 = 28.8, P = <0.0001, df = 1).
All women who consented for an interview were asked if they had been previously tested for 
HIV and had received results back from this test. Seventy-six women reported that they had 
been diagnosed with HIV infection at any time in the past (Table 3). Of the 2773 women 
who had reported having previously tested HIV-negative during their last pregnancy, 81 
(2.9%) were found to have laboratory-confirmed HIV infection in the survey contributing to 
almost half (47.4%) of all 171 HIV-positive tests in our study population (data not shown).
Among women who had had at least 1 live birth within the 5 years preceding the survey, the 
large majority (95.4%, 95% CI: 94.3 to 96.4) had attended an ANC clinic at least 1 time 
during their last pregnancy, and among these, 61.7% (95% CI: 59.0 to 64.5) had attended the 
recommended 4 or more visits (Table 3). Two-thirds (66.0%, 95% CI: 63.9 to 68.1) of 
women had presented for ANC in their second trimester, and 19.1% (95% CI: 17.4 to 20.9) 
presented in their first trimester. Of the women who had attended an ANC clinic, 93.1% 
(95% CI: 91.5 to 94.7) accepted HIV testing at the facility, 1.6% (95% CI: 1.1 to 2.1) had 
been offered but refused testing, and 5.3% (95% CI: 3.7 to 6.9) had not been offered a HIV 
test at the ANC clinic. Of those who had been tested for HIV at ANC, 97.8% (95% CI: 97.2 
to 98.4) received their HIV results. Of women who received results, 2.9% (95% CI: 2.0 to 
3.8) reported that they had been diagnosed with HIV during their last pregnancy or were 
known to be infected before their last pregnancy.
All women reporting a previous HIV-positive diagnosis had received prenatal care; 80.5% 
(95% CI: 69.7 to 91.3) had their first visit to the ANC in their second trimester or earlier, 
and 56.5% (95% CI: 44.7 to 68.2) attended for the recommended 4 ANC visits (Table 4). 
About three-quarters (72.3%, 95% CI: 61.0 to 83.5) of diagnosed women reported that they 
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had received antepartum antiretroviral prophylaxis during their pregnancy, 69.1% (95% CI: 
56.5 to 81.7) reported receiving intrapartum prophylaxis at labor or delivery, and, among 
mothers who had breastfed their infants, 83.1% (95% CI: 73.2 to 93.1) reported taking 
maternal prophylaxis while breastfeed-ing. Three-quarters (75.3%, 95% CI: 64.8 to 85.8) of 
diagnosed mothers reported that their newborns received postpartum pro-phylaxis at 
delivery, and 80.4% (95% CI: 68.6 to 92.1) reported that their babies received prophylaxis 
during breastfeeding. Of all diagnosed women, 90.1% (95% CI: 82.3 to 97.8) reported they 
received either maternal or infant prophylaxis during their pregnancy. Of children born to 
diagnosed mothers, 82.5% (95% CI: 73.0 to 92.1) of mothers reported that their children 
were tested for HIV at their first immunization visit or later, and 15.1% (95% CI: 2.4 to 
27.8) of these these children were reported by the mothers to be HIV-positive.
Women Whose Last Birth Was Within the 2 Years Preceding the Survey
Of the 1524 women who had given birth within the 2 years preceding the survey, 79 (5.1%) 
were found to have laboratory-confirmed HIV infection in KAIS 2012 (Table 4). Most HIV-
infected women reported receiving prenatal care at an ANC clinic (96.2%, 95% CI: 90.9 to 
100.0), 56.3% (95% CI: 44.0 to 68.6) attended an ANC at least 4 times during their 
pregnancy, and 78.6% (95% CI: 68.2 to 88.9) made their first ANC clinic visit in their 
second trimester or earlier. The majority of HIV-infected women (84.7%, 95% CI: 74.6 to 
94.8) were tested for HIV at the ANC clinic during their last pregnancy, with slightly more 
than half (55.6%, 95% CI: 42.3 to 68.9) who reported they were diagnosed with HIV at the 
ANC or at any time before that pregnancy. Among all infected women, 42.9% (95% CI: 
31.2 to 54.5) received antepartum antiretroviral prophylaxis during their pregnancy, 38.8% 
(95% CI: 25.6 to 51.9) received intrapartum prophylaxis at labor or delivery, and, among 
those who breastfed their baby, 46.8% (95% CI: 32.2 to 61.4) received antiretro-viral drugs 
while breastfeeding. For infant prophylaxis, 42.9% (95% CI: 31.2 to 54.5) of mothers 
reported that their newborns received prophylaxis at delivery, and, among those who 
breastfed their baby, 45.8% (95% CI: 33.7 to 57.9) of babies received infant prophylaxis 
while breastfeeding. Overall, 52.8% (95% CI: 39.2 to 66.4) of infected mothers received any 
form of maternal or infant prophylaxis during their last pregnancy. Among infants born to 
HIV-infected mothers, 44.4% (95% CI: 31.3 to 57.5) infants had been tested for HIV at the 
time of their first immunization visit or later.
Figure 1 illustrates the cascade of PMTCT care for women with laboratory-confirmed HIV 
infection whose last birth was within the 2 years preceding the survey, with coverage 
reflected as percentages within the bars and access reflected as percentages between the 
bars. With respect to access, of the 96.2% of women who had visited an ANC clinic during 
pregnancy in the previous 2 years, 88.1% were tested for HIV infection at ANC. Of those, 
59.6% were diagnosed HIV-positive at ANC or had reported previous HIV-positive 
diagnosis. Among women with diagnosed infection, 94.9% received any form of maternal or 
infant prophylaxis for PMTCT, and of those, 78.7% reported that their infant had been tested 
for HIV at the first immunization visit or later. For children who were tested, 7.4% (95% CI: 
0.0 to 15.9) were reported by the mother to be HIV-positive, 85.4% (95% CI: 74.0 to 96.9) 
were HIV-negative, 3.3% (95% CI: 0.0 to 9.7) had indeterminate results, and 3.9% (95% CI: 
0.0 to 9.3) of mothers did not disclose the results.
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We found that 6.1% of women in our nationally representative sample who had delivered 
infants in the preceding 5 years were infected with HIV. Of concern, about half were 
unaware of their HIV infection before participating in the survey. Although this may reflect 
intercurrent infection since their last pregnancy, it may also reflect low HIV risk perception, 
not having sought testing outside of ANC, reluctance to report HIV infection, denial or lack 
of understanding of previous diagnosis, or false-negative laboratory results. However, we 
did find an overall improvement in HIV testing among ANC clinic attendees during their 
pregnancy and in comparison to KAIS 2007, where testing rates significantly increased from 
64.9% (95% CI: 62.3 to 67.5) in 2007 to 93.1% (95% CI: 91.5 to 94.7) in 2012.12
Among women who reported that they had been diagnosed with HIV in their last pregnancy 
within the 5 years preceding the survey or were known to be infected before their last 
pregnancy, reported use of any form of maternal or infant antiretroviral prophylaxis was 
over 90%, with antiretroviral prophylaxis provided to about two-thirds of women and 75% 
of HIV exposed infants. Although these findings are encouraging, findings from our 
subanalysis of HIV-infected women whose last birth was within the 2 years preceding the 
survey were less so, revealing large gaps in the PMTCT cascade when HIV infection 
remains undiagnosed. With only 56% of HIV-infected women reporting a previous HIV-
positive diagnosis at ANC in their last pregnancy or at any time before their last pregnancy, 
use of maternal antiretroviral prophylaxis during breastfeeding, a practice recommended by 
the World Health Organization and in the national guidelines on postpartum prophylaxis, 
was reported by <50%.6,13 Moreover, infant prophylaxis was provided only to 46% of 
babies during breastfeeding. Additionally, coverage of any form of maternal or infant 
prophylaxis among women who were in need of PMTCT was low, at 53%. Of the infants 
likely exposed to HIV infection, only 44% had been tested. This is consistent with the 
national program estimate for coverage of early infant diagnosis over the same period of 
time, which improved from 23% in 2009 to 68% in 2012.9 Finally, we found that 83% of 
exposed infants whose mothers knew they were infected were reported to have been tested 
for HIV at the first immunization visit or later and calculated a cumulative MTCT rate of 
15.1% (95% CI: 2.4 to 27.8) over a 5-year period. Although this estimate reflects potential 
transmission for births that occurred in the past 5 years, this rate is similar to the current 
program transmission rates as determined by PCR before 1 year of age, which ranges from 
10% to 15% and overlaps with the confidence bounds of published rates from a research 
cohort in western Kenya.14,15 Notably, because of small sample sizes, the uncertainty 
around our 5-year cumulative MTCT estimate is wide, with a lower bound of 2.4% and an 
upper bound of 27.8%. Therefore, caution should be used in interpreting this finding.
Our study had several limitations. All exposure history was from mother’s self-report, and it 
was not possible to corroborate reported information with clinic records. Given the phrasing 
of the questionnaire, we were unable to differentiate which mothers began lifelong ART and 
who received antiretroviral prophylaxis but stopped at cessation of breastfeeding.16 The 
timing of infant PCR testing was not precisely determined, and we can only report that 
infants were diagnosed at their first immunization visit or later. In the subanalysis of HIV-
infected women who had given birth in the 2 years preceding the survey, assessment of 
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coverage of and access to PMTCT interventions assumed that these women were in need of 
PMTCT. However, despite high HIV testing rates among pregnant women attending ANC 
clinics, we found that only half of women with laboratory-confirmed HIV infection in the 
survey reported they were previously diagnosed with HIV at ANC or at any point before that 
visit. This suggests that some of these women may have been unwilling to disclose their 
HIV status, had false-negative results on previous tests, or became infected after their last 
live birth. Consequently, the low prevalence of reported HIV diagnosis in this subgroup may 
be an underestimate of the true prevalence of diagnosed HIV infection among women who 
recently gave birth.
With over half of potentially exposed infants untested in our subanalysis of women with 
laboratory-confirmed HIV infection, the documented MTCT rate of 7.4% among those 
tested for HIV may be unreliable because of a small sample size. Nonetheless, the particular 
strengths of our study are its nationally representative framework and our determination of 
actual HIV status by laboratory testing. Moreover, for women who have completed all steps 
in the PMTCT cascade, the MTCT rate is plausible.
In conclusion, we found that there remains a substantial burden of HIV among Kenyan 
women of child-bearing age. About 40% of HIV-infected women and 45% of exposed 
infants did not receive antiretroviral prophylaxis, highlighting current challenges in the 
PMTCT cascade. However, the proportion of women who reported being screened for HIV 
at ANC has risen substantially since 2007. We also were encouraged to see that once 
diagnosed, 90% of HIV-infected pregnant women received any form of maternal or infant 
PMTCT prophylaxis. Provision of lifelong ART for pregnant women at diagnosis will be an 
essential step toward realizing the national goal of eliminating MTCT to <5% by 2015. As 
the national PMTCT program prepares to transition from prophylactic ART to universal 
ART, routine cohort analyses among HIV-infected pregnant women will be needed to track 
the national scale-up of this intervention and respond to challenges encountered.
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TABLE 1
Characteristics of Women Who Had ≥1 Live Births in the 5 Years Preceding the Survey, Kenya AIDS 
Indicator Survey 2012
N = 3310
Variable Unweighted, n Weighted % (95% CI)
Age group, yrs
 ≤24 1105 33.7 (31.5 to 35.9)
 25–29 928 28.3 (26.5 to 30.1)
 30–39 1007 30.3 (28.1 to 32.6)
 >40 270 7.7 (6.6 to 8.7)
Marital status
 Never married/never cohabited 307 9.5 (8.1 to 10.9)
 Ever widowed 82 2.5 (1.9 to 3.2)
 Divorced/separated 159 4.8 (3.9 to 5.7)
 Married/cohabiting 2762 83.2 (81.6 to 84.7)
Does husband have other wives?
 Yes 336 9.3 (7.6 to 11.0)
 No 2974 90.7 (89.0 to 92.4)
Highest educational attainment
 No primary 506 9.1 (6.3 to 11.9)
 Incomplete primary 278 8.0 (6.5 to 9.4)
 Complete primary 1084 35.9 (33.3 to 38.4)
 Secondary or higher 1442 47.1 (44.4 to 49.8)
Region
 Nairobi 346 9.2 (7.9 to 10.6)
 Central 300 10.6 (8.9 to 12.3)
 Coast 416 9.1 (7.4 to 10.8)
 Eastern 696 14.8 (12.8 to 16.8)
 Nyanza 455 15.4 (13.5 to 17.2)
 Rift Valley 671 29.1 (26.0 to 32.2)
 Western 426 11.8 (10.2 to 13.4)
Residence
 Rural 2165 65.1 (62.2 to 68.0)
 Urban 1145 34.9 (32.0 to 37.8)
Wealth index
 Poorest 826 23.4 (20.0 to 26.9)
 Second 729 22.2 (19.8 to 23.1)
 Middle 655 20.6 (18.1 to 23.9)
 Fourth 539 16.3 (14.0 to 18.7)
 Richest 561 17.5 (14.8 to 20.2)
Desires more children in the future*
 Yes 1484 41.5 (39.0 to 44.0)
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N = 3310
Variable Unweighted, n Weighted % (95% CI)
 No 1511 48.6 (46.0 to 51.1)
 Undecided/do not know 302 9.5 (8.1 to 10.8)
*
Category frequencies do not add to the total because of missing responses.
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TABLE 3
ANC Interventions for PMTCT Among Women Who Had ≥1 Live Births Within the 5 Years Preceding the 
Survey, Kenya AIDS Indicator Survey 2012
Intervention Unweighted, n Weighted % (95% CI)
Attended ANC clinic during pregnancy (N = 3310)
 Yes 3132 95.4 (94.3 to 96.4)
 No 178 4.6 (3.6 to 5.7)
Number of ANC visits among women who attended (N = 3132)
 1 96 3.1 (2.4 to 3.9)
 2–3 1027 33.9 (31.4 to 36.5)
 ≥4 1969 61.7 (59.0 to 64.5)
 Does not know 40 1.2 (0.7 to 1.7)
Timing of first ANC visit among women who attended (N = 3132)
 0–3 months 623 19.1 (17.4 to 20.9)
 4–6 months 2061 66.0 (63.9 to 68.1)
 7–9 months 415 13.7 (12.1 to 15.3)
 Does not know 33 1.1 (0.7 to 1.6)
HIV tested at ANC visit among women who attended (N = 3132)
 Tested at ANC 2924 93.1 (91.5 to 94.7)
 Offered but not tested 45 1.6 (1.1 to 2.1)
 Not offered 163 5.3 (3.7 to 6.9)
Received HIV results among women tested (N = 2924)
 Yes 2865 97.8 (97.2 to 98.4)
 No 59 2.2 (1.6 to 2.8)
HIV status (N = 2869)
 HIV-negative 2773 96.4 (95.4 to 97.4)
 HIV-positive* 76 2.9 (2.0 to 3.8)
 Unwilling to disclose 20 0.69 (0.4 to 1.0)
Place of birth (N = 3310)
 Home 1472 42.3 (38.9 to 45.7)
 Hospital 1820 57.1 (53.8 to 60.5)
 Other place 18 0.60 (0.3 to 0.9)
*
Includes 4 women who already knew they were HIV-positive.
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TABLE 4
Access to and Coverage of ANC Interventions for PMTCT Among Women Who Were Known to be HIV 
Infected Who Had ≥1 Live Births Within the 5 Years Preceding the Survey and Women with Laboratory-
Confirmed HIV Infection Whose Last Birth Was Within the 2 Years Preceding the Survey, Kenya AIDS 
Indicator Survey 2012
Women Who Had ≥1 Live Births Within the 5 
Years Preceding the Survey and Who Were 
Diagnosed With HIV During or Before Their 
Last Pregnancy (N = 76)
Women with Laboratory-Confirmed HIV 
Infection Whose Last Birth Was Within the 2 
Years Preceding the Survey (N = 79)
Intervention Unweighted, n
Weighted % (95% 
CI) Unweighted, n Weighted % (95% CI)
Attended ANC clinic during pregnancy
 Yes 76 100 76 96.2 (90.9 to 100.0)
 No 0 — 3 3.8 (0 to 9.1)*
Number of ANC visits
 1–3 27 42.7 (30.9 to 54.4) 33 39.9 (28.2 to 51.6)
 ≥4 48 56.5 (44.7 to 68.2) 43 56.3 (44.0 to 68.6)
 Does not know 1 0.9 (0 to 2.6)* 0 —
 Did not attend ANC 0 — 3 3.8 (0 to 9.1)*
Timing of first ANC visit
 ≤6 months 62 80.5 (69.7 to 91.3) 19 78.6 (68.2 to 88.9)
 7–9 months 14 19.4 (8.7 to 30.2)* 14 17.6 (7.9 to 27.4)*
 Did not attend ANC 0 — 3 3.8 (0 to 9.1)*
HIV tested at ANC visit
 Yes 76 100 69 84.7 (74.6 to 94.8)
 No 0 — 7 11.5 (2.4 to 20.5)*
 Did not attend ANC 0 — 3 3.8 (0 to 9.1)*
Diagnosed with HIV at ANC visit
 Yes 76† 100 40† 55.6 (42.3 to 68.9)
 No 0 — 36 40.6 (27.6 to 53.6)
 Did not attend ANC 0 — 3 3.8 (0 to 9.1)*
Maternal use of ARVs
 During pregnancy 54 72.3 (61.0 to 83.5) 29 42.9 (30.6 to 55.2)
 During labor/delivery 51 69.1 (56.5 to 81.7) 26 38.8 (25.6 to 51.9)
 During breastfeeding‡ 53 83.1 (73.2 to 93.1) 33 46.8 (32.2 to 61.4)
 No maternal use of ARVs 6 7.6 (1.2 to 14.0)* 39 43.9 (30.6 to 57.1)
Place of birth
 Home 25 31.0 (15.7 to 46.3)* 29 35.5 (22.8 to 48.3)
 Hospital 51 69.0 (53.7 to 84.3) 49 64.5 (50.6 to 76.2)
 Other 0 — 1 1.1 (0 to 3.3)*
Postpartum infant ARV prophylaxis
 After delivery 56 75.3 (64.8 to 85.8) 30 42.9 (31.2 to 54.5)
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Women Who Had ≥1 Live Births Within the 5 
Years Preceding the Survey and Who Were 
Diagnosed With HIV During or Before Their 
Last Pregnancy (N = 76)
Women with Laboratory-Confirmed HIV 
Infection Whose Last Birth Was Within the 2 
Years Preceding the Survey (N = 79)
Intervention Unweighted, n
Weighted % (95% 
CI) Unweighted, n Weighted % (95% CI)
 During breastfeeding‡ 51 80.4 (68.6 to 92.1) 33 45.8 (33.7 to 57.9)
No postpartum infant ARV 
prophylaxis
8 8.7 (2.4 to 15.0)* 38 45.0 (32.8 to 57.3)
Any form of maternal or infant 
prophylaxis
69 90.1 (82.3 to 97.8) 38 52.8 (39.2 to 66.4)
No form of maternal or infant 
prophylaxis
7 10.0 (2.2 to 17.7)* 41 47.2 (33.6 to 60.8)
Child tested for HIV at first immunization visit or later§
 Yes 63 82.5 (73.0 to 92.1) 32 44.4 (31.3 to 57.5)
 No 13 17.5 (8.0 to 27.0)* 47 55.6 (42.6 to 68.7)
Child’s HIV test result (reported by mother)
 Positive 8/63 15.1 (2.4 to 27.8)* 3/32 7.4 (0 to 15.9)*
 Negative 50/63 77.6 (64.1 to 91.0) 26/32 85.4 (74.0 to 96.9)
 Unknown|| 5/63 6.0 (0.5 to 11.6)* 3/32 7.2 (0 to 15.3)*
 Child did not test for HIV 13 — 47 —
ARV, antiretroviral drug.
*
Because of a small sample size, this estimate may be unreliable.
†
Includes 4 women who already knew they were HIV-positive.
‡
Excludes women who did not breastfeed.
§
This analysis includes children who may not have yet reached the recommended age for the first immunization visit.
||
Unknown status includes mothers who did not disclose test results or reported the result as indeterminate.
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